Three genetic loci for lung cancer risk have been identified by genome-wide association studies (GWAS), but inherited susceptibility to specific histologic types of lung cancer is not well established. We conducted a GWAS of lung cancer and its major histologic types, genotyping 515,922 single-nucleotide polymorphisms (SNPs) in 5739 lung cancer cases and 5848 controls from one population-based casecontrol study and three cohort studies. Results were combined with summary data from ten additional studies, for a total of 13,300 cases and 19,666 controls of European descent. Four studies also provided histology data for replication, resulting in 3333 adenocarcinomas (AD), 2589 squamous cell carcinomas (SQ), and 1418 small cell carcinomas (SC). In analyses by histology, rs2736100 (TERT), on chromosome 5p15. 
adenocarcinoma (AD) and squamous cell carcinoma (SQ), along with rarer subtypes. Worldwide, adenocarcinoma is the most frequently identified histologic type, and the relative proportion of lung cancer due to this histology has steadily risen. Demographic, etiologic, clinical, and molecular characteristics of the lung cancer subtypes have been reported. 7 Although family history of lung cancer has been associated with histologic subtypes, [8] [9] [10] [11] the inherited susceptibility factors that affect specific histologies are unknown.
We conducted a GWAS in 5739 lung cancer cases and 5848 controls (National Cancer Institute [NCI] GWAS) to search for overall susceptibility variants and variants associated with specific histologic types and smoking status. We also conducted a meta-analysis of the NCI GWAS with summary data from ten additional studies, for a total of 13,300 primary lung cancer cases and 19,666 controls, all of European descent. Four of the ten studies provided information on histology for replication analyses; 3333 AD, 2589 SQ, and 1418 SC cases were analyzed overall.
The 11,587 subjects in the NCI GWAS were drawn from one population-based case-control study and three cohort studies ( GWAS included 1730 AD cases, 1400 SQ cases, 678 SC cases, and groups of other histological types or of mixed histologies. These studies were approved by the individual institutional review boards of each location, and each subject gave his or her informed consent for participation. The meta-analysis included all of the NCI GWAS data plus summary data from ten additional studies contributing 7561 cases and 13,818 controls ( In both the NCI GWAS and the studies in the meta-analysis, the lung cancer diagnosis was based on clinical criteria and confirmed by pathology reports from surgery, biopsy, or cytology samples in approximately 95% of cases and on clinical history and imaging for the remaining 5%. Tumor histology was coded according to the International Classification of Diseases for Oncology. In analyses stratified by histology, only adenocarcinoma, squamous cell carcinoma, and small cell carcinoma cases were included. All mixed subtypes or other histologies were excluded. Overall, between 10% and 50% of all diagnoses from the NCI GWAS were centrally reviewed by expert lung pathologists from NCI.
The NCI GWAS scan was conducted at two institutions: the Center for Inherited Disease Research (CIDR), which genotyped all EAGLE and 1675 PLCO subjects, and the Core Genotyping Facility (CGF), NCI, which genotyped ATBC, CPS-II, and the remaining PLCO subjects. Controls from the Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer scan 22 were also included.
EAGLE samples and 1675 PLCO samples were genotyped at CIDR, as part of the Gene Environment Association Studies Initiative (GENEVA) funded through the National Human Genome Research Institute, with the use of Illumina HumanHap550v3_B BeadChips (Illumina, San Diego, CA, USA). Data were released for 5620 of 5727 (98%) samples, including 32 blind duplicates (concordance was 99.993%); these were genotyped with 124 HapMap controls (66 CEU; 58 YRI). Allele cluster definitions per SNP were determined with the use of the Illumina BeadStudio Genotyping Module version 3.1.14 and the combined intensity data from 95% of the samples. The resulting cluster definitions were used on all samples. Genotypes were not called if the quality threshold (Gencall score) was below 0.15. Genotypes were released by CIDR for 560,505 (99.83% of attempted) SNPs. Genotypes were not released for SNPs not called by BeadStudio or for those with call rates less than 85%, more than one HapMap replicate error, more than a 3% (autosomal) or 5% (X chromosome) difference in call rate between genders, or more than 0.5% male AB frequency for the X chromosome. The mean non-Y chromosome SNP call rate and mean sample call rate were each 99.8% for the CIDR data set.
Similar procedures were followed at CGF for the ATBC, CPSII, and PLCO cohorts with the use of three Illumina platforms: the HumanHap550K, the HumanHap610, and HumanHap 1 Million chips. All genotyped samples passed quality control metrics at CGF. After removal of assay and locus as a result of low completion rates, genotypes for each sample that appeared in duplicate were merged to form consensus genotypes for each subject. There were
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A total of 221 pairs of samples were identified with >70% genotype concordance rate. Among them, 189 pairs were expected duplicates and had genotype concordance rates > 99.9%. There were 12 unexpected duplicates (cross or within studies) with >99.97% concordance rates. We evaluated the pairwise concordance on the basis of the entire set and observed 40 pairs of subjects with over 60% of concordant genotypes (genotype concordance > 60%). Exclusions are listed in Table S2 . Deviations from Hardy-Weinberg proportions (HWP) were assessed in controls. Expected and observed p values were calculated with the use of the uniform distribution for all loci and the exact test, respectively. Autosomal SNPs with minor allele frequencies (MAFs) >5% and completion rates >95% were included. Deviation from HWP was minimal, and only loci with extremely low p values (p < 10 À7 ) for each QC group were excluded from further analyses (Table S3) . A quantile-quantile (Q-Q) plot of the p values per study is shown in Figure S2 .
To assess population structure, we estimated imputed continental ancestry by using the STRUCTURE program, 23 with a set of 12,898 autosomal SNPs with low local background linkage disequilibrium (LD) (pairwise r 2 < 0.004 measured in the population of European ancestry for any pair of SNPs less than 500 kb apart) 24 ( Figure S3 ). Genotypes from the three HapMap populations (Build 22 for HapMap II with MAF > 5%) 25 were used as reference populations. The number of inferred clusters (''K'' parameter) was set to 3 for CEU, YRI, and JPTþCHB samples representing populations of European, African, and Asian origin, respectively. Eighteen subjects were detected as having less than 80% European ancestry and were excluded. Principal component analysis (PCA) for each study group (excluding subjects with less than 80% European ancestry, unexpected duplicates, and potential relative pairs) was performed with the same informative 12,898 SNPs with the use of the EIGENSTRAT program 26 ( Figures   S4A-S4D ). After adjustment for significant principal components (PCs) in each study, comparison of observed and expected distributions showed no evidence for largescale inflation of the association test statistics (inflation factor l ¼ 1.03, 103, 1.01, and 1.01 in EAGLE, PLCO, CPS-II, and ATBC, respectively), excluding the possibility of significant hidden population substructure. Q-Q plots for each NCI study are shown in Figures S5A-S5D. After excluding 183 subjects for the reasons described above (summarized in Table S2 ) and 337 subjects with incomplete phenotype data, we report analyses on 515,922 SNPs in 5739 lung cancer cases and 5848 controls (NCI GWAS, Table 1 ).
Comparable QC procedures were conducted at each institution that provided summary results for the metaanalysis. [1] [2] [3] [4] [5] For the genome-wide analysis of the NCI GWAS, we used unconditional logistic regression to derive a per-allele odds ratio (OR) and an associated 1 degree of freedom (df) association test adjusted for age in five-year intervals (defined as age at diagnosis or interview for the case-control study and as baseline age for cohort studies), gender, study (EAGLE, PLCO, ATBC, ACS), and four PCs for population stratification within studies (see description of PC analysis below). In additional analyses, we adjusted for smoking status (current, former, never), cigarettes smoked per day (% 10, 11-20, 21-30, 31-40, 41þ), duration in 10 yr intervals, and number of years since quitting (1-5, 6-10, 11-20, 21-30, 30þ) for former smokers (subjects who quit smoking at least 6 mo before participating in the study). The analyses with single and multiple SNPs stratified by histology, smoking status, and decade of birth were conducted with the use of the same models. Tests for interaction between a SNP (coded as a continuous variable) and smoking status or birth decade (coded with the use of dummy variables) were performed with Wald tests with the use of multiple dfs.
For the meta-analysis with other studies, we obtained per-allele ORs and standard errors from each study. Because only summary data were available, we conducted the meta-analysis in two separate groups: ''Set 1 SNPs'' included a core of 279,698 SNPs that were available across all studies; and ''Set 2 SNPs'' included 197,647 SNPs that were available only for a subset of the studies that used the HumanHap500 or denser genomic platforms or provided summary data on imputed SNPs. We obtained meta-analysis estimates of per-allele ORs and associated p values by using the weighted Z-score method under a fixed effect model. 27 Tests for heterogeneity by study were performed with the use of the Q E statistics, assuming a random effect model. For testing of heterogeneity across histologic subtypes, we reported the smallest p values obtained from pairwise case-case analyses between the subtypes after adjustment for multiple testing with the use of the Bonferroni correction. All odds-ratios were reported with respect to the minor allele in the pooled set of controls from all studies that contributed to the meta-analysis. For adjustment of population stratification, we used the same set of 12,898 autosomal informative SNPs 24 used for QC. We conducted PCA in each of the four study groups (EAGLE, PLCO, ATBC, and CPS-II) separately. 27 For each study group, we identified among the top ten PCs the ones on which lung cancer cases and controls were not distributed evenly (the Wilcoxon rank-sum test p < 0.1), and adjusted them as continuous covariates nested within each study group. We selected two PCs for PLCO and one for each EAGLE and ATBC. No PCs were selected for the CPS-II study. Of note, we replicated the major analyses by using PCs obtained from all SNPs and found virtually identical results (data not shown).
Genome-wide analysis of the NCI GWAS confirmed previously reported findings on 5p15, 15q25, and 6p21, but did not conclusively identify novel susceptibility loci for lung cancer risk. Similar results were obtained in the overall meta-analysis combining the NCI GWAS with results from the ten additional studies, for a total of over 30,000 subjects ( Figure 1 and Table S5 ).
The analysis of the locus on the 5p15.33 region [4] [5] [6] provided notable findings. In the overall analysis of the NCI GWAS, the most prominent SNPs were rs4635969 Table 2 ). rs2736100 showed discrepant results by smoking status (Table 2) , which reflected different associations across histologies. In fact, this locus showed remarkable differences by histology ( Figure 2 (Table 2 ) revealed that the SNP was significantly associated with risk of adenocarcinoma in both smokers and those who had never smoked. In the NCI controls, rs2736100 is not in LD with other tested SNPs in the region (Figure 2) Table S5 ). In analyses by histology, risk associated with rs2736100 was accounted for by cases with adenocarcinoma in each replication study (p < 0.05 in each study; p ¼ 0.59, test for heterogeneity across studies) (Figure 3 ). Other histologies exhibited no association. In the metaanalysis combining the NCI GWAS data with the data from the Texas, deCODE, HGF, and UK studies, this SNP had OR ¼ (Table 2) . These findings provide evidence that the previously identified association of the rs2736100 variant on 5p15.33 with lung cancer risk 4,5 is confined to one histologic type, adenocarcinoma. Rs2736100 is located in intron 2 of TERT and, on the basis of the ESPERR score, lies within a putative regulatory region. 28 TERT is a ribonucleoprotein that extends TTAGGG nucleotide repeats at the telomere, which shorten with each cell division. Telomere shortening is associated with increased genomic instability and, consequently, increased risk of cancer development. 29 In cancer cells, reactivated TERT is linked to cellular proliferation and abnormal telomere maintenance. 30 Other studies have suggested that perturbations of TERT may contribute to the pathogenesis of lung adenocarcinoma. TERTexpression has been reported to be significantly lower in adenocarcinoma than in any other histological type, 31 and its reexpression may indicate progression from bronchiolo-alveolar carcinoma to adenocarcinoma. The Overall meta-analyses include four NCI GWAS studies plus ten additional studies; the meta-analyses in the three major histologic types include four NCI GWAS studies plus four replication studies for the SNPs on chromosome 5p15 and three replication studies for the SNPs on chromosome 15q25. Results for each SNP are shown in this order: Top row (NCI_Smoking Unadjusted), results from the NCI GWAS data adjusted for age in five-year intervals (defined as age-at-diagnosis/interview for case-control study and age at baseline for cohort study), gender, study (EAGLE, PLCO, ATBC, CPS-II) and four principal components for population stratification within studies (two for PLCO, and one each for EAGLE and ATBC). Adjustment for the same variables plus smoking status (current, former, never), cigarettes smoked per day (%10, 11-20, 21-30, 31-40, 41þ), duration in ten-year intervals and number of years since quitting (1-5, 6-10, 11-20, 21-30, 30þ) for former smokers showed virtually identical results (data not shown). Second row (NCI_Current smokers), results from the NCI GWAS data restricted to current smoker subjects, adjusted for the same variables of the top row. Third row (NCI_Former smokers), results from the NCI GWAS data restricted to former smoker subjects who quit smoking > 6 months prior to the study, adjusted for the same variables of the top row. Fourth row (NCI_Never smokers), results from the NCI GWAS data restricted to never smoker subjects who smoked < 100 cigarettes in their lifetime, adjusted for the same variables of the top row. Bottom row (Meta-analysis Unadjusted), results from the meta-analysis combining NCI GWAS data and ten additional studies, unadjusted models. a NCBI dbSNP identifier. TERT has been reported to promote epithelial proliferation, 34 whereas telomere maintenance has been implicated in the progression from KRAS-activated adenoma to adenocarcinoma in murine models. 35 rs2736100 was recently found in association with lung cancer risk in two populations, with suggestive stronger associations in adenocarcinoma cases, female cases, and case individuals who had never smoked. 36, 37 Interestingly, rs2736100 has been reported to be associated with susceptibility to sporadic idiopathic pulmonary fibrosis (IPF), 38, 39 whereas rare mutations in TERT and consequent shorter telomeres are responsible for familial IPF. 40 IPF is a lethal disease characterized by massive fibrotic changes and thickening of the alveolar walls in the lung. Members of IPF families frequently develop lung adenocarcinoma, suggesting that these two diseases share a common etiology. 41 Furthermore, telomerase dysfunction has been linked to leukemia, bone marrow failure, and cancer predisposition, [42] [43] [44] and other SNPs in the TERT-CLPTM1L region have been found in association with multiple cancer types, 6 suggesting that this region possesses a fundamental key for cancer development. rs2736100 and other SNPs in the locus are close to the location of known mutations that compromise telomerase activity ( Figure 4 ) and may be in LD with mutations that have yet to be identified. Complete sequencing of this locus in adenocarcinoma patients would enable a more comprehensive understanding of the variants associated with this signal.
The NCI GWAS also refined other previously identified susceptibility loci. [1] [2] [3] 5 The strongest evidence for association with lung cancer risk overall and with each histology group was observed for the 15q25.1 locus. (Table 2 ; a longer SNP list in given in Table   S5 ). The same SNPs were also strongly associated with all major histology groups ( Table 2 ). There were 20 SNPs at this locus with p < 10 À7 and 15
after adjustment for multiple smoking variables, suggesting that the association of these SNPs with lung cancer risk is not entirely explained by the association with smoking or that residual confounding by smoking cannot be completely ruled out. In the analysis of the NCI GWAS stratified by smoking status (Table 2) , SNPs on 15q25 showed a very strong association in current and former smokers but no association in those who had never smoked, as previously observed in some, 2, 45 but not all, 1 studies. The interaction between these SNPs and smoking status was borderline significant (p ¼ 0.07, p ¼ 0.07, and p ¼ 0.04 for rs12914385, rs1051730, and rs8034191, respectively).
We conducted an analysis stratified by decade of birth (<1930, 1930-1939, 1940-1949 , and >1950) to explore whether the complex changes in cigarette composition and population trends in cigarette smoking affected the association between this locus and lung cancer risk. Most subjects in our study were born in the 1930s-1940s and began smoking approximately 15-20 years after birth. Thus, smokers were affected by the progressive adoption of cigarette filters and alterations in tar, nicotine, and nitrosamine content in cigarettes that began in the 1950s. 46 For the top SNPs on 15q25, we observed a trend of increasing lung cancer risk with more recent decades of birth both overall and in each histology group, with the exception of the SQ cases (Table 3) . Because widespread cigarette smoking generally began a few years later in Europe than in the U.S., we stratified the analyses between American (PLCO and CPS-II) and European (EAGLE and ATBC) studies. As expected, the American studies showed a slightly stronger association (data not shown). One possible explanation for the increasing risk in more recent decades of birth is that the association of chromosome 15q25 SNPs with lung cancer risk is mediated in part by the increasing nitrosamine content in cigarettes over the second half of the 20 th century. 47, 48 Carcinogenic nitrosamines are thought to bind to the nicotinic receptor, 49 and carriers of the 15q25 locus are exposed to a higher internal dose of nitrosamines per cigarette than are noncarriers. 50 No clear trend by decade of birth was observed for squamous cell carcinoma, possibly because this histologic type is more strongly associated with polycyclic aromatic hydrocarbons than with nitrosamines. 47, 48, 51 However, these findings may be affected by small numbers in subgroups and should be further explored. A recent study from the UK reported that the 6p21.33 locus is associated with lung cancer risk, 5 and a suggestive association for another SNP in the region (rs4324798 on 6p22.1) had been previously shown. 1 In the meta-analysis, SNPs at this locus were associated with lung cancer risk (Table S4) . However, the association varied by study and was weak in the NCI GWAS and in the studies used in replicating the analysis by histology (Table S4 ). These SNPs are located near the major histocompatibility complex and thus could be markers for differences in population substructure. In this study including over 30,000 subjects, no new genomic regions associated with lung cancer risk were identified. This contrasts with studies of other cancer types, such as breast, colon, and prostate cancers, which observed multiple common susceptibility loci in similar or smaller sample sizes. [52] [53] [54] It is plausible that additional genetic variation for smoking-related cancers will be revealed through the investigation of interaction with tobacco smoking or structural variants. Our findings are based on subjects of European descent only; further work is necessary for the exploration of whether additional loci or different variants in the same loci are associated with lung cancer risk in distinct populations.
In conclusion, we have established that a locus on chromosome 5p15.33 is distinctly associated with risk of lung adenocarcinoma and not with the other major histologic types, providing evidence of histology-specific germ-line susceptibility for lung cancer risk. Defining the distinct hereditary contribution to histological subtypes and their interplay with tobacco smoking is a step on the pathway to the molecular characterization of cancer and could lead to improved measures for early detection or prevention.
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